par Abdel Azim, Hatem Hamdy 
;Piccart-Gebhart, Martine
Référence Expert review of anticancer therapy, 10, 8, page (1255-1263)
Publication Publié, 2010-08
;Piccart-Gebhart, Martine Référence Expert review of anticancer therapy, 10, 8, page (1255-1263)
Publication Publié, 2010-08
Article révisé par les pairs
| Résumé : | Approximately 50% of HER2-positive breast cancers express estrogen receptor (ER) and these tumors are characterized by short-lived responses to hormonal agents. Preclinical models have shown that dual targeting of ER and HER2 could reverse and delay the development of drug resistance. Two studies (TAnDEM & EGF3008) have recently been published addressing the combined use of an aromatase inhibitor (AI) and an anti-HER2-targeted agent. Both studies showed that the combined approach is associated with improvement in response rate and progression-free survival compared with an AI alone with an acceptable toxicity profile. These results would indeed extend the treatment options for patients with ER/HER2-positive metastatic breast cancer. In this article, we discuss how the improved understanding of the complex cross-talk between ER and HER2 has resulted in better clinical outcomes. We analyze clinical evidence regarding the combined use of AIs and anti-HER2-targeted agents. We also touch on possible mechanisms of resistance and ways to improve research in this field. |
